{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:44:24Z","timestamp":1793504664564,"version":"4.5.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venous thromboembolism (VTE) is a prevalent and serious complication among cancer patients, necessitating therapeutic anticoagulation for many individuals with brain metastases. Simultaneously, patients with brain metastases, particularly those with high-risk primary tumors, have an increased risk of intracranial hemorrhage (ICH). Managing anticoagulation in these patients presents a dual challenge: preventing thromboembolism while avoiding hemorrhagic events. Here, we present our approach to anticoagulation for acute VTE in patients with brain metastases, based on the available evidence. We review potential risk factors for anticoagulation-associated ICH in this population and discuss strategies for managing acute VTE in patients with and without ICH.<\/jats:p>","DOI":"10.1182\/hematology.2024000660","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:02:45Z","timestamp":1733497365000},"page":"246-252","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Management of anticoagulation in patients with brain metastasis"],"prefix":"10.1182","volume":"2024","author":[{"given":"Eva. N.","family":"Hamuly\u00e1k","sequence":"first","affiliation":[{"name":"1 Department of Internal Medicine, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Yust-Katz","sequence":"additional","affiliation":[{"name":"2 Neurooncology Unit, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Leader","sequence":"additional","affiliation":[{"name":"3 Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"14","key":"2024121115350916000_hem2024000660C1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024121115350916000_hem2024000660C2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"2024121115350916000_hem2024000660C3","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor- bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024121115350916000_hem2024000660C4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2024121115350916000_hem2024000660C5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024121115350916000_hem2024000660C6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2024121115350916000_hem2024000660C7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115350916000_hem2024000660C8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"2024121115350916000_hem2024000660C9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jocn.2020.08.006","article-title":"The primary sites leading to brain metastases: shifting trends at a tertiary care center","volume":"80","author":"Bhambhvani","year":"2020","journal-title":"J Clin Neurosci"},{"issue":"16","key":"2024121115350916000_hem2024000660C10","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024121115350916000_hem2024000660C11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.hest.2022.01.005","article-title":"Hemorrhage in brain tumor\u2014an unresolved issue","volume":"3","author":"Ostrowski","year":"2022","journal-title":"Brain Hemorrhages"},{"issue":"7","key":"2024121115350916000_hem2024000660C12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2024121115350916000_hem2024000660C13","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor XA inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2024121115350916000_hem2024000660C14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2024121115350916000_hem2024000660C15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2024121115350916000_hem2024000660C16","first-page":"781","article-title":"CASTA DIVA Trial Investigators. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Bura-Rivi\u00e8re","year":"2022","journal-title":"Chest"},{"issue":"22","key":"2024121115350916000_hem2024000660C17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"2024121115350916000_hem2024000660C18","first-page":"34","article-title":"Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study","volume-title":"Lancet Reg Health Eur","author":"S\u00f8rensen","year":"2023"},{"issue":"1","key":"2024121115350916000_hem2024000660C19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2024121115350916000_hem2024000660C20","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases","volume":"4","author":"Leader","year":"2020","journal-title":"Blood Adv"},{"key":"2024121115350916000_hem2024000660C21","doi-asserted-by":"crossref","first-page":"100611","DOI":"10.1016\/j.rpth.2023.100611","article-title":"Intracranial hemorrhage in patients with brain metastases receiving anticoagulation (ABC study)","volume":"7","author":"Hamuly\u00e1k","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2024121115350916000_hem2024000660C22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2024121115350916000_hem2024000660C23","first-page":"9","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs","author":"Galgani","year":"2018","journal-title":"Front Neurol"},{"issue":"5","key":"2024121115350916000_hem2024000660C24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40263-024-01077-0","article-title":"The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations","volume":"38","author":"Goldstein","year":"2024","journal-title":"CNS Drugs"},{"issue":"7","key":"2024121115350916000_hem2024000660C25","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"2024121115350916000_hem2024000660C26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-020-6569-1","article-title":"Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial","volume":"20","author":"Lesueur","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"2024121115350916000_hem2024000660C27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11060-022-04178-2","article-title":"Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases","volume":"160","author":"McKenzie","year":"2022","journal-title":"J Neurooncol"},{"issue":"10","key":"2024121115350916000_hem2024000660C28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102391","article-title":"Factors associated with hemorrhage of melanoma brain metastases after stereotactic radiosurgery in the era of targeted\/immune checkpoint inhibitor therapies","volume":"14","author":"Zoga","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"48","key":"2024121115350916000_hem2024000660C29","doi-asserted-by":"crossref","first-page":"e28069","DOI":"10.1097\/MD.0000000000028069","article-title":"Clinico-radiological features of brain metastases from thyroid cancer","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2024121115350916000_hem2024000660C30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2007.08.053","article-title":"High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor","volume":"53","author":"Pouessel","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"2024121115350916000_hem2024000660C31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","article-title":"French Group on Renal Cancer. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases","volume":"12","author":"Chevreau","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"25","key":"2024121115350916000_hem2024000660C32","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"Mantia","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024121115350916000_hem2024000660C33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12928-020-00642-w","article-title":"Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective","volume":"35","author":"Mangieri","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"issue":"6","key":"2024121115350916000_hem2024000660C34","first-page":"362","article-title":"Lower extremity peripheral artery disease: diagnosis and treatment","volume":"99","author":"Firnhaber","year":"2019","journal-title":"Am Fam Physician"},{"issue":"3","key":"2024121115350916000_hem2024000660C35","first-page":"CD000029","article-title":"Oral antiplatelet therapy for acute ischaemic stroke","volume":"2014","author":"Sandercock","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2024121115350916000_hem2024000660C36","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1212\/WNL.0000000000004694","article-title":"Low-dose aspirin and risk of intracranial bleeds: an observational study in UK general practice","volume":"89","author":"Cea Soriano","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"2024121115350916000_hem2024000660C37","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/bloodadvances.2021006470","article-title":"Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors","volume":"6","author":"Miller","year":"2022","journal-title":"Blood Adv"},{"key":"2024121115350916000_hem2024000660C38","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"Xiao","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2024121115350916000_hem2024000660C39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-011-0642-1","article-title":"Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients","volume":"106","author":"Norden","year":"2012","journal-title":"J Neurooncol"},{"issue":"13","key":"2024121115350916000_hem2024000660C40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013 vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"2024121115350916000_hem2024000660C41","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies\u2014TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"Wang","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2024121115350916000_hem2024000660C42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"2024121115350916000_hem2024000660C43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/cancers14030465","article-title":"Intracranial hemorrhage in patients with anticoagulant therapy undergoing stereotactic radiosurgery for brain metastases: a bi-institutional analysis","volume":"14","author":"Ehret","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2024121115350916000_hem2024000660C44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/jnnp-2020-325299","article-title":"Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants","volume":"92","author":"Seiffge","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2024121115350916000_hem2024000660C45","first-page":"43","article-title":"Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control","volume":"3","author":"Ghia","year":"2014","journal-title":"J Radiosurg SBRT"},{"issue":"5","key":"2024121115350916000_hem2024000660C46","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/rth2.12377","article-title":"Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism","volume":"4","author":"Carney","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"17","key":"2024121115350916000_hem2024000660C47","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2024121115350916000_hem2024000660C48","doi-asserted-by":"crossref","first-page":"0","DOI":"10.3324\/haematol.2023.284192","article-title":"Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer","volume":"109","author":"Patell","year":"2023","journal-title":"Haematologic"},{"issue":"2","key":"2024121115350916000_hem2024000660C49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ene.13830","article-title":"Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage","volume":"26","author":"Ianosi","year":"2019","journal-title":"Eur J Neurol"},{"issue":"5","key":"2024121115350916000_hem2024000660C50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/NRL.0000000000000141","article-title":"Early versus delayed initiation of pharmacological venous thromboembolism prophylaxis after an intracranial hemorrhage","volume":"22","author":"Faust","year":"2017","journal-title":"Neurologist"},{"issue":"4","key":"2024121115350916000_hem2024000660C51","first-page":"CD013422","article-title":"Treatment of distal deep vein thrombosis","volume":"4","author":"Kirkilesis","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2024121115350916000_hem2024000660C52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jamacardio.2022.1988","article-title":"RIETE Investigators. Clinical presentation and short- and long-term outcomes in patients with isolated distal deep vein thrombosis vs proximal deep vein thrombosis in the RIETE registry","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2024121115350916000_hem2024000660C53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M21-2981","article-title":"SSPE Investigators. Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation: a multicenter prospective cohort study","volume":"175","author":"Le Gal","year":"2022","journal-title":"Ann Intern Med"},{"issue":"5","key":"2024121115350916000_hem2024000660C54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.23.00429","article-title":"RIETE Investigators. Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis","volume":"42","author":"Galanaud","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024121115350916000_hem2024000660C55","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1055\/a-1742-0177","article-title":"Incidence and outcomes associated with 6,841 isolated distal deep vein thromboses in patients with 13 common cancers","volume":"122","author":"Mahajan","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024121115350916000_hem2024000660C56","first-page":"239","article-title":"Risk of recurrent venous thromboembolism and bleeding in patients with acute isolated subsegmental pulmonary embolism","author":"Girardi","year":"2024","journal-title":"Thromb Res"},{"issue":"8","key":"2024121115350916000_hem2024000660C57","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1055\/s-0039-1688828","article-title":"Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry","volume":"119","author":"Ageno","year":"2019","journal-title":"Thromb Haemost"},{"issue":"7","key":"2024121115350916000_hem2024000660C58","doi-asserted-by":"crossref","first-page":"e2011079","DOI":"10.1001\/jamanetworkopen.2020.11079","article-title":"Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis","volume":"3","author":"Balabhadra","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2024121115350916000_hem2024000660C59","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1055\/s-0040-1710589","article-title":"Outcomes after vena cava filter use in patients with cancer-associated venous thromboembolism and contraindications to anticoagulation","volume":"120","author":"Quezada","year":"2020","journal-title":"Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/246\/2346363\/246hamulyak.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/246\/2346363\/246hamulyak.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T16:54:07Z","timestamp":1733936047000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/246\/526224\/Management-of-anticoagulation-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000660","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}